Skip to main content

Advertisement

SpringerLink
Log in

Coaxil (tianeptine) in the treatment of depression in Parkinson’s disease

  • Published:
Neuroscience and Behavioral Physiology Aims and scope Submit manuscript

Abstract

An open, non-comparative clinical study was performed to assess the efficacy and safety of tianeptine (Coaxil) in Parkinson’s disease (PD). A total of 18 patients with PD were used whose clinical state increased moderately severe and more profound depression (assessed on the Hamilton and Beck scales). After three months of treatment, depression on the Hamilton depression scale was decreased by 34% and on the Beck scale by 31% compared with baseline data (p < 0.05). Improvements in mental status were noted in 14 of 18 patients (77%); eight patients (44%) showed more than 50% reductions on the Hamilton scale. Analysis of the structure of depressive symptomatology showed that improvement occurred because of decreases in anxiety and the severity of somatoform symptoms and, to a lesser extent, in melancholy and sleep disturbance. There was no significant change in apathy. The decrease in the severity of depression was accompanied by an improvement in the quality of life. The efficacy of Coaxil was greater in patients with less marked depressive and motor symptoms, shorter durations of illness, and less marked cognitive impairments. Coaxil was well tolerated by the patients. The data obtained here provide grounds for recommending the use of Coaxil in the treatment of depression in PD.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Zh. M. Glozman, V. N. Shtok, N. M. Saltykova, et al., “Clinical psychological investigations of depressive syndrome in Parkinson’s disease,” Vestn. Mosk. Gos. Univ., Series 14, 3, 29–36 (1995).

    Google Scholar 

  2. Zh. M. Glozman and O. S. Levin, “Mental impairments in extrapyramidal disorders,” in: Extrapyramidal Disorders [in Russian], V. N. Shtok, I. A. Ivanova-Smolenskaya, and O. S. Levin (eds.), Moscow (2002), pp. 74–86.

  3. Zh. M. Glozman, O. S. Levin, and N. Yu. Lycheva, “Impairments of emotional memory and the recognition of emotional states in patients with Parkinson’s disease,” Fiziol. Cheloveka, 6, 55–60 (2003).

    Google Scholar 

  4. V. L. Golubev, Ya. I. Levin, and A. M. Vein, Parkinson’s Disease and Parkinsonism Syndrome [in Russian], Moscow (1999).

  5. O. S. Levin, “Treatment of early-stage Parkinson’s disease,” in: The World of Medicines [in Russian] (2001), Vol. 1, pp. 41–47.

    Google Scholar 

  6. O. S. Levin, “Mental disorders in Parkinson’s disease and their correction,” in: Extrapyramidal Disorders: A Handbook of Diagnosis and Treatment [in Russian], V. N. Shtok, I. A. Ivanova-Smolenskaya, and O. S. Levin (eds.), Medpress-inform, Moscow (2002), pp. 125–152.

    Google Scholar 

  7. O. S. Levin, Clinical-Neuropsychological and Neuroimaging Aspects of the Differential Diagnosis of Parkinsonism [in Russian], Author’s abstract of thesis for doctorate in medical sciences, Moscow (2003).

  8. O. S. Levin, Difficult Problems in the Treatment of Parkinson’s Disease and Pathways to Their Solution [in Russian], Moscow (2003).

  9. O. S. Levin, Zh. M. Glozman, and N. Yu. Lycheva, “The internal picture of illness and the quality of life of patients with Parkinson’s disease,” in: A. R. Luriya and Psychology in the 21st Century [in Russian], T. V. Akhutina and Z. H. Glozman (eds.), Moscow (2003), pp. 114–121.

  10. O. S. Levin, I. G. Smolentseva, and B. Tseredsodnom, “The effects of dopaminergic therapy on neuropsychological functions in patients with Parkinson’s disease,” Nevrol. Zh., 3, 31–37 (2004).

    Google Scholar 

  11. International Statistical Classification of Diseases and Health-Related Problems [Russian translation], WHO, Geneva (1998), 10th edition, Vol. 1.

  12. S. N. Mosolov, Clinical Use of Contemporary Antidepressants [in Russian], MIA, St. Petersburg (2003).

    Google Scholar 

  13. I. G. Smolentseva, The Effects of Dopamine Receptor Agonists on Motor and Neuropsychological Disorders in Patients with Parkinson’s Disease [in Russian], Author’s abstract of thesis for doctorate in medical sciences, Moscow (2000).

  14. A. B. Smulevich, Depression in Somatic and Mental Diseases [in Russian], MIA, Moscow (2003).

    Google Scholar 

  15. V. N. Shtok, O. S. Levin, and N. V. Fedorova, Extrapyramidal Disorders [in Russian], MIA, Moscow (2002).

    Google Scholar 

  16. D. Aarsland, J. P. Larsen, N. G. Lim, et al., “Range of neuropsychiatric disturbances in patients with Parkinson’s disease,” J. Neurol., 67, 492–496 (1999).

    CAS  Google Scholar 

  17. Y. Agid, F. Javoy-Agid, and M. Ruberg, “Biochemistry of neurotransmitters in Parkinson’s disease, ” in: Movement Disorders 2, C. D. Marsden and S. Fahn (eds.), Butterworths, London (1987), pp. 166–230.

    Google Scholar 

  18. G. Alexopoulos, “The depression-executive dysfunction syndrome of late life,” Amer. J. Geriatr. Psychiatr., 9, 22–29 (2001).

    Article  CAS  Google Scholar 

  19. A. T. Beck, C. H. Ward, M. Mendelson, et al., “An inventory for measuring depression,” Arch. Gen. Psychiatr., 4, 561–571 (1961).

    PubMed  CAS  Google Scholar 

  20. H. Braak, K. Del Tredici, H. Bratzke, et al., “Staging of the intracerebral inclusion body pathology associated with idiopathic Parkinson’s disease (preclinical and clinical stages),” J. Neurol., 249, Supplement 3, 1–5 (2002).

    Article  Google Scholar 

  21. R. Brooks, R. Rabin, and F. de Charro, The Measurement and Valuation of Health Status Using EQ-5D, Kluwer Academic Publishers, Dordrecht (2003).

    Google Scholar 

  22. D. J. Burn, “Beyond the iron mask: towards better recognition and treatment of depression associated with Parkinson’s disease,” Mov. Dis., 17, 445–454

  23. J. L. Cummings, “Depression in Parkinson’s disease,” Amer. J. Psychiat., 149, 443–454 (1992).

    PubMed  CAS  Google Scholar 

  24. J. L. Cummings, “Frontal-subcortical circuits and human behavior,” Arch. Neurol., 50, 873–880 (1993).

    PubMed  CAS  Google Scholar 

  25. EuroQoL Group, “EuroQoL: a new facility for the measurement of health-related quality of life,” Health Policy, 16, 199–208 (1990).

    Article  Google Scholar 

  26. S. Fahn and R. L. Elton, “Unified rating scale for Parkinson’s disease,” in: Recent Developments in Parkinson’s Disease, S. Fahn and C. D. Marsden (eds.), Macmillan, Florham Park, New York (1987), pp. 153–163.

    Google Scholar 

  27. W. Gibb and A. Lees, “The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson’s disease,” J. Neurol. Neurosurg. Psychiatr., 51, 745–752 (1988).

    Article  PubMed  CAS  Google Scholar 

  28. J. D. Guelfi, C. Dulcire, P. Lemoine, et al., “Clinical safety and efficacy of tianeptine in 1858 depressed patients in general practice,” Neuropsychology, 25, 140–148 (1992).

    CAS  Google Scholar 

  29. M. Hamilton, “A rating scale for depression,” J. Neurol. Neurosurg. Psychiatr., 23, 56–62 (1960).

    PubMed  CAS  Google Scholar 

  30. M. Hillen and J. I. Sage, “Nonmotor fluctuations in patients with Parkinson’s disease,” Neurology, 47, 1180–1183 (1996).

    PubMed  CAS  Google Scholar 

  31. M. Hoehn and M. D. Jahr, “Parkinsonism: onset, progression and mortality,” Neurology, 17, No. 5, 427–442 (1967).

    Article  PubMed  CAS  Google Scholar 

  32. T. Klaassen, “Treatment of depression in Parkinson’s disease,” J. Neuropsychiat. Clin. Neurosci., 7, 281–286 (1995).

    CAS  Google Scholar 

  33. A. F. G. Leentjens, J. Martinus, J. J. van Hilten, et al., “The contribution of somatic symptoms to the diagnosis of depressive disorder in Parkinson’s disease: A discriminant analytic approach,” J. Neuropsychiat. Clin. Neurosci., 15, 74–77 (2003).

    CAS  Google Scholar 

  34. A. F. G. Leentjens, “Depression in Parkinson’s disease: conceptual issues and clinical challenges, ” J. Geriatr. Psychiatr. Neurol., 17, 120–126 (2004).

    Article  Google Scholar 

  35. O. S. Levin and V. N. Shtock, Disconnection Between Cognitive and Emotional Functions as a Factor of Dementia in Parkinson’s Disease and Subcortical Vascular Encephalopathy, Eurobrain, Aasborg (1997).

    Google Scholar 

  36. M. L. Levy, J. L. Cummings, L. A. Fairbanks, et al., “Apathy is not depression,” J. Neuropsychiat. Clin. Neurosci., 10, 314–319 (1998).

    CAS  Google Scholar 

  37. S. Mattis, Dementia Rating Scale: Professional Manual, Psychological Assessment Resources, Odessa, FL (1988).

    Google Scholar 

  38. J. Parkinson, An Essay on the Shaking Palsy, London (1817).

  39. G. C. Pluck and R. G. Brown, “Apathy in Parkinson’s disease,” J. Neurol. Neurosurg. Psychiatr., 73, 636–642 (2002).

    Article  PubMed  CAS  Google Scholar 

  40. I. H. Richard, R. Kurlan, C. Tanner, et al., “Serotonin syndrome and the combined use of deprenyl and an antidepressant in Parkinson’s disease,” Neurology, 48, 1070–1077 (1997).

    PubMed  CAS  Google Scholar 

  41. A. Shrag, M. Jahanshahi, and N. Quinn, “What contributes to depression in Parkinson’s disease?” Psychol. Med., 31, 65–73 (2001).

    Article  Google Scholar 

  42. L. M. Shulman, R. L. Taback, and A. A. Rabinstein, “Non-recognition of depression and other non-motor symptoms in Parkinson’s disease,” in: Parkinsonism and Related Disorders (2002).

  43. J. R. Slaughter, K. A. Slaughter, D. Nichols, et al., “Prevalence, clinical manifestations, etiology and treatment of depression in Parkinson’s disease,” J. Neuropsychiatr. Clin. Neurosci., 13, 187–196 (2001).

    CAS  Google Scholar 

  44. S. E. Starkstein, M. L. Berthier, P. L. Bolduc, et al., “Depression in patients with early versus late onset of Parkinson’s disease,” Neurology, 39, 1441–1445 (1989).

    PubMed  CAS  Google Scholar 

  45. S. E. Starkstein and M. Merello, Psychiatric and Cognitive Disorders in Parkinson’s Disease, Cambridge University Press (2002).

  46. D. Weintraub, P. J. Moberg, J. E. Duda, et al., “Recognition and treatment of depression in Parkinson’s disease,” J. Geriatr. Psychiatr. Neurol., 16, 178–183 (2003).

    Article  Google Scholar 

  47. D. Weintraub, K. H. Morales, P. J. Moberg, et al., “Antidepressant studies in Parkinson’s disease: a review and meta-analysis,” Mov. Dis., 20, 1161–1169 (2005).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurology, Russian Medical Academy of Postgraduate Education, Russia

    O. S. Levin

  2. Center for Extrapyramidal Diseases, Federal Health Agency, Moscow

    O. S. Levin

Authors
  1. O. S. Levin
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

__________

Translated from Zhurnal Nevrologii i Psikhiatrii imeni S. S. Korsakova, Vol. 106, No. 3, pp. 20–25, March, 2006.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Levin, O.S. Coaxil (tianeptine) in the treatment of depression in Parkinson’s disease. Neurosci Behav Physiol 37, 419–424 (2007). https://doi.org/10.1007/s11055-007-0029-0

Download citation

  • Received:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11055-007-0029-0

Key words

Search

Navigation